Max S. Topp

机构：University of Würzburg, Universitätsklinikum Würzburg · ORCID：0000-0002-1267-5289

发表论文 295 篇 · 总被引 18402 次 · h-index 57

代表论文

• Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial (2024 · The Lancet · 被引 140)
• Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy (2023 · Blood · 被引 60)
• EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma (2024 · Journal for ImmunoTherapy of Cancer · 被引 48)
• Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 (2025 · Leukemia · 被引 40)
• Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): Preliminary Results of the GMALL Bold Trial (2023 · Blood · 被引 39)
• Odronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study (2024 · Blood · 被引 32)